Insider Trading activities of Point Therapeutics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Point Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Point Therapeutics Inc since year 2005. Table 2 shows the detailed insider transactions of Point Therapeutics Inc since 2005. The reporting company's ticker symbol is POTP. The reporting company's CIK number is 919745.
The total value of stock buying since 2005 is $324,536.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $210,750.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Point Therapeutics Inc (POTP).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2013-06 14,000 $9,982 0 $0 0 $0
2013-05 45,000 $31,930 0 $0 0 $0
2012-09 30,000 $30,512 0 $0 0 $0
2012-07 10,000 $7,324 0 $0 0 $0
2012-06 25,000 $19,250 0 $0 0 $0
2012-05 25,000 $22,525 0 $0 0 $0
2011-04 3,500 $9,730 0 $0 0 $0
2010-09 5,000 $13,200 0 $0 0 $0
2010-08 5,000 $11,450 0 $0 0 $0
2010-05 6,096 $24,729 0 $0 0 $0
2010-02 0 $0 0 $0 400,000 $100,000
2009-09 0 $0 0 $0 425,000 $110,750
2008-02 19,200 $40,404 0 $0 0 $0
2005-11 34,500 $103,500 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Point Therapeutics Inc insiders (POTP)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-06-03 Clement Christopher G (President) Buy 14,000 .71 9,982
2013-05-30 Cochrane Haywood D (Director) Buy 10,000 .70 7,000
2013-05-23 Heady Timothy James (Director) Buy 10,000 .75 7,480
2013-05-17 Drutz David (CEO and CMO) Buy 25,000 .70 17,450
2012-09-17 Drutz David (CEO and CMO) Buy 25,000 1.06 26,500
2012-09-11 Cochrane Haywood D (Director) Buy 2,800 .82 2,296
2012-09-10 Cochrane Haywood D (Director) Buy 2,200 .78 1,716
2012-07-20 Cochrane Haywood D (Director) Buy 9,000 .73 6,579
2012-07-19 Cochrane Haywood D (Director) Buy 1,000 .74 745
2012-06-08 Drutz David (CEO and CMO) Buy 25,000 .77 19,250
2012-05-29 Drutz David (CEO and CMO) Buy 25,000 .90 22,525
2011-04-26 Franco Richard A (President & CEO) Buy 3,500 2.78 9,730
2010-09-02 Franco Richard A (President & CEO) Buy 5,000 2.64 13,200
2010-08-31 Franco Richard A (President & CEO) Buy 5,000 2.29 11,450
2010-05-24 Franco Richard A (President & CEO) Buy 2,000 4.18 8,360
2010-05-20 Franco Richard A (President & CEO) Buy 1,000 4.45 4,450
2010-05-19 Franco Richard A (President & CEO) Buy 3,096 3.85 11,919
2010-02-11 Franco Richard A (President & CEO) Option Ex 400,000 .25 100,000
2009-09-24 Rosar Ann A (Chief Accounting Officer) Option Ex 25,000 .43 10,750
2009-09-24 Franco Richard A (President & CEO) Option Ex 400,000 .25 100,000
2008-02-22 Didsbury John (Chief Scientific Officer) Buy 9,000 2.34 21,024
2008-02-22 Franco Richard A (Chairman, President and CEO) Buy 10,200 1.90 19,380
2005-11-21 Barberich Timothy J (Chief Executive Officer) Buy 34,500 3.00 103,500

Insider trading activities including stock purchases, stock sales, and option exercises of POTP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Point Therapeutics Inc (symbol POTP, CIK number 919745) see the Securities and Exchange Commission (SEC) website.